ArticleJournal of neurology2022

Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis.

Massimo Filippi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.